Is ABUS or ACAD more undervalued in 2026?

CirclFi compares Arbutus Biopharma Corporation (ABUS) and ACADIA Pharmaceuticals Inc. (ACAD) using 13 institutional-grade valuation models. ABUS has a Quality of Company score of 7.0/10 while ACAD scores 9.4/10.

Which is a better buy — ABUS or ACAD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ABUS and ACAD valuations compare?

ABUS at $4.60 and ACAD at $21.63 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ABUS vs ACAD Valuation Comparison 2026 — Intrinsic Value Analysis

ABUS

Biotechnology

Arbutus Biopharma Corporation

Quality

7.0

out of 10

Value Trap

SAFE

Price

$4.60

Last close

Models

9/13

Active

ACAD

Biotechnology

ACADIA Pharmaceuticals Inc.

Quality

9.4

out of 10

Value Trap

SAFE

Price

$21.63

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	ABUS Fair Value	ABUS Upside	ACAD Fair Value	ACAD Upside
Bayesian DCF	Intrinsic	$1.29	-72.0%	$22.90	+5.9%
Earnings Power Value	Intrinsic	—	—	$3.82	-82.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$4.54	+2.2%	$52.03	+140.6%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABUS vs ACAD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABUS vs ACAD — Which Stock Is More Undervalued?

ACAD scores higher with a 9.4/10 quality rating vs ABUS's 7.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Arbutus Biopharma Corporation (ABUS) and ACADIA Pharmaceuticals Inc. (ACAD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABUS currently trades at $4.60 with a QOC of 7.0/10, while ACAD trades at $21.63 with a QOC of 9.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).